Pharmaceutical

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval

Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy).

Apr 23, 2024 - 00:00
Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy).
Read the original article

Tags:

Previous Article

AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NE...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Adenocarcinoma of The Pa...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

RAPT terminates Phase II trials for lead candidate following clinical hold

RAPT terminates Phase II trials for lead candidate foll...

May 11, 2024

STAT+: J&J cuts the price of its lifesaving TB pill by more than half for many low- and middle-income countries

STAT+: J&J cuts the price of its lifesaving TB pill by ...

Aug 31, 2023

Opinion: How kangaroo mother care can help millions of babies each year

Opinion: How kangaroo mother care can help millions of ...

Oct 12, 2023